Epigenic Therapeutics
Epigenetic Tx (益杰立科) is a cutting-edge biotechnology company founded in 2021, focused on developing next-generation gene regulation therapies by targeting epigenetic modifications. Their proprietary EPIREG® technology platform utilizes AI algorithms and CRISPR-Cas systems to precisely modulate gene expression without altering the DNA sequence. This platform, combined with their in-house LNP/mRNA delivery system, has been validated in various in-vitro and in-vivo models for diseases including metabolic, cardiovascular, viral hepatitis, ocular, oncology, and rare diseases. The company has secured significant funding, including a $32 million Series A round. Epigenetic Tx aims to create long-lasting, safe gene therapies to improve quality of life and address unmet medical needs globally.
Epigenic Therapeutics
Epigenetic Tx (益杰立科) is a cutting-edge biotechnology company founded in 2021, focused on developing next-generation gene regulation therapies by targeting epigenetic modifications. Their proprietary EPIREG® technology platform utilizes AI algorithms and CRISPR-Cas systems to precisely modulate gene expression without altering the DNA sequence. This platform, combined with their in-house LNP/mRNA delivery system, has been validated in various in-vitro and in-vivo models for diseases including metabolic, cardiovascular, viral hepatitis, ocular, oncology, and rare diseases. The company has secured significant funding, including a $32 million Series A round. Epigenetic Tx aims to create long-lasting, safe gene therapies to improve quality of life and address unmet medical needs globally.